Clinical Trials Logo

KIT Exon 13 Mutation clinical trials

View clinical trials related to KIT Exon 13 Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03171389 Recruiting - GIST, Malignant Clinical Trials

POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST

POETIG
Start date: March 22, 2017
Phase: Phase 2
Study type: Interventional

This is a non-randomized, open-label, multicenter phase 2 study to evaluate the efficacy and safety of ponatinib in patients with metastatic and/or unresectable GIST after prior failure or intolerability of imatinib. Patients will be enrolled into 1 of 2 cohorts based on absence (Cohort A) or presence (Cohort B) of KIT exon 13 resistance mutations as measured by liquid biopsy. A third cohort (Cohort C) will include patients who have received all approved lines of TKI treatments (imatinib, sunitinib and regorafenib).